2021–2022 Drug Updates in Hematologic Malignancies

During JADPRO Live 2022, Jenni Tobin, PharmD, reviewed the indications of newly approved therapies in hematologic malignancies (including those for multiple myeloma, lymphoma, and acute leukemia) approved from late 2021 to late 2022. Dr. Tobin discussed their unique mechanisms of action, administrat...

Descripción completa

Detalles Bibliográficos
Autor principal: Tobin, Jenni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184846/
https://www.ncbi.nlm.nih.gov/pubmed/37197730
http://dx.doi.org/10.6004/jadpro.2023.14.3.10
_version_ 1785042222589149184
author Tobin, Jenni
author_facet Tobin, Jenni
author_sort Tobin, Jenni
collection PubMed
description During JADPRO Live 2022, Jenni Tobin, PharmD, reviewed the indications of newly approved therapies in hematologic malignancies (including those for multiple myeloma, lymphoma, and acute leukemia) approved from late 2021 to late 2022. Dr. Tobin discussed their unique mechanisms of action, administration, and how to monitor for and manage side effects associated with these new therapeutics.
format Online
Article
Text
id pubmed-10184846
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-101848462023-05-16 2021–2022 Drug Updates in Hematologic Malignancies Tobin, Jenni J Adv Pract Oncol Meeting Reports During JADPRO Live 2022, Jenni Tobin, PharmD, reviewed the indications of newly approved therapies in hematologic malignancies (including those for multiple myeloma, lymphoma, and acute leukemia) approved from late 2021 to late 2022. Dr. Tobin discussed their unique mechanisms of action, administration, and how to monitor for and manage side effects associated with these new therapeutics. Harborside Press LLC 2023-04 2023-04-01 /pmc/articles/PMC10184846/ /pubmed/37197730 http://dx.doi.org/10.6004/jadpro.2023.14.3.10 Text en © 2023 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Tobin, Jenni
2021–2022 Drug Updates in Hematologic Malignancies
title 2021–2022 Drug Updates in Hematologic Malignancies
title_full 2021–2022 Drug Updates in Hematologic Malignancies
title_fullStr 2021–2022 Drug Updates in Hematologic Malignancies
title_full_unstemmed 2021–2022 Drug Updates in Hematologic Malignancies
title_short 2021–2022 Drug Updates in Hematologic Malignancies
title_sort 2021–2022 drug updates in hematologic malignancies
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184846/
https://www.ncbi.nlm.nih.gov/pubmed/37197730
http://dx.doi.org/10.6004/jadpro.2023.14.3.10
work_keys_str_mv AT tobinjenni 20212022drugupdatesinhematologicmalignancies

Ejemplares similares